Indirect comparisons were performed using data from GOG-0179 versus GOG-0169 to permit
comparison of topotecan in combination with cisplatin versus cisplatin plus paclitaxel via
the common comparator of cisplatin monotherapy. Both GOG-0179 and GOG-0169 were conducted in
patients with stage IVB, recurrent or persistent carcinoma of the cervix, but there were some
differences between the respective study populations. Patients with prior chemotherapy were
eligible for GOG-0179 but ineligible for GOG-0169 (except when chemotherapy was used for
radiation sensitisation). Fewer patients had received chemotherapy as a radiosensitiser in
GOG-0169 (27%) than in GOG-0179 (~60%) and these patients were unevenly distributed between
treatment arms in GOG-0169. In addition, the proportion of patients receiving cisplatin as a
radiosensitiser in GOG-0169 is unknown. For these reasons, there are limitations associated
with the indirect meta-analysis.